This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n19http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/ontology/domain/vavai/
n18http://linked.opendata.cz/resource/domain/vavai/zamer/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F11%3A9450%21RIV12-MZ0-11110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F11%3A9450%21RIV12-MZ0-11110___
rdf:type
n9:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1007/s00432-010-0889-5
dcterms:description
Carriers of BRCA1/2 mutations are at high lifetime risk of breast cancer (BC); however, the BC onset broadly vary in individual patients. Recently, polyglutamine (poly-Q) repeat length polymorphism of the amplified in breast cancer 1 (AIB1) gene was analyzed as a risk factor influencing BC onset in BRCA1/2 mutation carriers with contradictory results. We genotyped AIB1 poly-Q repeat in 243 BRCA1/2 mutation carriers, 61 patients with familial BC (negatively tested for the presence of BRCA1/2 mutation), 221 patients with sporadic BC, and 176 non-cancer controls using denaturing high-performance liquid chromatography and statistically evaluated the effect of AIB1 poly-Q repeat length polymorphism on BC onset. Having used previously published statistical analyses of AIB1 poly-Q repeat length (a parts per thousand yen28 and a parts per thousand yen29 repeat cutpoints or analysis of AIB1 poly-Q repeat length as continuous variable), we did not find any association between AIB1 poly-Q repeat length and BC development in analyzed BC groups. However, the analysis of individual genotypes revealed that AIB1 genotype consisting of 28/28 glutamine repeats served as a protective factor in BRCA1 mutation carriers (HR = 0.64; 95% CI 0.41-0.99; P = 0.045) and as a risk factor in carriers of mutation in exon 11 of the BRCA2 gene (HR = 3.50; 95% CI 1.25-9.78; P = 0.017). Our results confirm that AIB1 poly-Q repeat length polymorphism does not influence the BC risk in general but suggest that the specific AIB1 genotypes should be considered in patients with BC carrying mutation in the BRCA1/2 genes. Carriers of BRCA1/2 mutations are at high lifetime risk of breast cancer (BC); however, the BC onset broadly vary in individual patients. Recently, polyglutamine (poly-Q) repeat length polymorphism of the amplified in breast cancer 1 (AIB1) gene was analyzed as a risk factor influencing BC onset in BRCA1/2 mutation carriers with contradictory results. We genotyped AIB1 poly-Q repeat in 243 BRCA1/2 mutation carriers, 61 patients with familial BC (negatively tested for the presence of BRCA1/2 mutation), 221 patients with sporadic BC, and 176 non-cancer controls using denaturing high-performance liquid chromatography and statistically evaluated the effect of AIB1 poly-Q repeat length polymorphism on BC onset. Having used previously published statistical analyses of AIB1 poly-Q repeat length (a parts per thousand yen28 and a parts per thousand yen29 repeat cutpoints or analysis of AIB1 poly-Q repeat length as continuous variable), we did not find any association between AIB1 poly-Q repeat length and BC development in analyzed BC groups. However, the analysis of individual genotypes revealed that AIB1 genotype consisting of 28/28 glutamine repeats served as a protective factor in BRCA1 mutation carriers (HR = 0.64; 95% CI 0.41-0.99; P = 0.045) and as a risk factor in carriers of mutation in exon 11 of the BRCA2 gene (HR = 3.50; 95% CI 1.25-9.78; P = 0.017). Our results confirm that AIB1 poly-Q repeat length polymorphism does not influence the BC risk in general but suggest that the specific AIB1 genotypes should be considered in patients with BC carrying mutation in the BRCA1/2 genes.
dcterms:title
The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development
skos:prefLabel
The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development
skos:notation
RIV/00216208:11110/11:9450!RIV12-MZ0-11110___
n9:predkladatel
n10:orjk%3A11110
n3:aktivita
n8:Z n8:I n8:P
n3:aktivity
I, P(NS10304), Z(MSM0021620808), Z(MZ0MOU2005)
n3:cisloPeriodika
2
n3:dodaniDat
n11:2012
n3:domaciTvurceVysledku
n5:4280229 n5:6104347 n5:2973278 n5:5825156 n5:7191642
n3:druhVysledku
n14:J
n3:duvernostUdaju
n6:S
n3:entitaPredkladatele
n16:predkladatel
n3:idSjednocenehoVysledku
184902
n3:idVysledku
RIV/00216208:11110/11:9450
n3:jazykVysledku
n15:eng
n3:klicovaSlova
Amplified in breast cancer 1 (AIB1/SRC-3/NCoA3) gene; Polymorphism; CAA/CAG repeat; Breast cancer; BRCA1; BRCA2; estrogen; position
n3:klicoveSlovo
n4:estrogen n4:BRCA1 n4:CAA%2FCAG%20repeat n4:BRCA2 n4:Polymorphism n4:Breast%20cancer n4:position n4:Amplified%20in%20breast%20cancer%201%20%28AIB1%2FSRC-3%2FNCoA3%29%20gene
n3:kodStatuVydavatele
DE - Spolková republika Německo
n3:kontrolniKodProRIV
[45F760FC5DFB]
n3:nazevZdroje
Journal of Cancer Research and Clinical Oncology
n3:obor
n20:FD
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
10
n3:projekt
n19:NS10304
n3:rokUplatneniVysledku
n11:2011
n3:svazekPeriodika
137
n3:tvurceVysledku
Pohlreich, Petr Foretová, Lenka Soukupová, Jana Janatová, Markéta Kormunda, Stanislav Macháčková, Eva Tavandzis, Spiros Havránek, Ondřej Kleibl, Zdeněk Novotný, Jan
n3:wos
000286106000018
n3:zamer
n18:MZ0MOU2005 n18:MSM0021620808
s:issn
0171-5216
s:numberOfPages
8
n12:organizacniJednotka
11110